2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Nervous System Injury
  5. Spinal Cord Injury

Spinal Cord Injury

Spinal cord injury (SCI) refers to damage to the spinal cord resulting in impaired motor and/or sensory function below the level of injury, which can be either complete or incomplete. It disrupts communication between the brain and body, commonly due to vertebral fractures or dislocations, leading to symptoms such as paralysis, numbness, weakness, loss of bladder control, pain, and respiratory difficulties. The severity and manifestations depend on the location and extent of the injury. Immediate medical intervention—including medications, surgical stabilization, bracing, and rehabilitation—is critical to minimize long-term disability. The condition involves complex neural pathways, with GDNF (Glial Cell Derived Neurotrophic Factor) identified as a key associated gene, and pathways like Signal Transduction and MIF Mediated Glucocorticoid Regulation implicated. Drugs such as Mecamylamine and Zoledronic acid have been explored in treatment contexts, and affected tissues include bone, adipose, and spinal cord, with phenotypes linked to nervous system dysfunction and abnormalities in growth or body region development.

Spinal Cord Injury (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176803
    MF-DH-300 2673403-86-4 99.53%
    MF-DH-300 is a 15-PGDH inhibitor that can be applicable to the research of muscle disorders such as spinal muscular atrophy (SMA).
    MF-DH-300
  • HY-B0464A
    Hydralazine 86-54-4 99.94%
    Hydralazine is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain.
    Hydralazine
  • HY-19667
    BMS-561392 611227-74-8
    BMS-561392 (BMS-561392) is a selective ADAM17(TACE) inhibitor. BMS-561392 inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 can be used in research related to spinal cord injury and inflammatory diseases.
    BMS-561392